Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Med ; 12(6): 7116-7126, 2023 03.
Article in English | MEDLINE | ID: mdl-36478416

ABSTRACT

BACKGROUND: Rituximab, high-dose methotrexate (HD-MTX), procarbazine and vincristine (R-MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R-MPV have not yet been investigated. Herein, we investigated the correlation of MYD88 L265P and CD79B Y196 mutations, which are the most frequently found molecular alterations in PCNSL, with prognosis of patients with PCNSL treated with R-MPV. METHODS: We investigated the long-term clinical course and status of MYD88 and CD79B genes in 85 patients with PCNSL treated with R-MPV or HD-MTX treatment, and the correlation of these genetic mutations with prognosis. RESULTS: R-MPV achieved an excellent tumor control rate (61.6% and 69.9% of 5-year progression-free and overall survival rates, respectively). While MYD88 L265P mutation had no significant effect on survival, patients with CD79B Y196 mutations exhibited prolonged survival (p < 0.05). However, the association of CD79B Y196 mutation with a better prognosis was not observed in the HD-MTX cohort, which indicated that CD79B Y196 mutation was a predictive marker for a favorable response to R-MPV. Furthermore, we established an all-in-one rapid genotyping system for these genetic mutations. CONCLUSIONS: In conclusion, CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in PCNSL. The rapid identification of MYD88 L265P and CD79B Y196 mutations can be helpful not only for the accurate molecular diagnosis of PCNSL but also for the prediction of response to R-MPV.


Subject(s)
Central Nervous System Neoplasms , Lymphoma, Large B-Cell, Diffuse , Humans , Lymphoma, Large B-Cell, Diffuse/drug therapy , Myeloid Differentiation Factor 88/genetics , Myeloid Differentiation Factor 88/metabolism , Mutation , Rituximab/therapeutic use , Central Nervous System/metabolism , Central Nervous System/pathology , Central Nervous System Neoplasms/drug therapy , Central Nervous System Neoplasms/genetics , Methotrexate/therapeutic use , CD79 Antigens/genetics
2.
World Neurosurg ; 126: 24-29, 2019 06.
Article in English | MEDLINE | ID: mdl-30844533

ABSTRACT

BACKGROUND: Posterior cerebral artery (PCA) aneurysms are relatively rare, and neck clipping is often difficult due to their fusiform shape. We report a case of a thrombosed aneurysm of the distal PCA for which curative trapping and parent artery reconstruction by in situ bypass were performed through an occipital transtentorial approach (OTA). CASE DESCRIPTION: A 67-year-old woman had been suffering from numbness in the right face and limbs for 4 months. Radiologic imaging demonstrated a thrombosed aneurysm on a distal portion of the left PCA. Curative trapping of the aneurysm and in-situ bypass between the distal PCA and superior cerebellar artery were performed through the OTA. Before surgery, we had evaluated access to the PCA and feasibility of the bypass in a cadaveric simulation. The PCA was well exposed in the posterior half of the ambient cistern, and the proximity of the distal PCA to the superior cerebellar artery through a tentorial incision was confirmed. CONCLUSIONS: This OTA could represent a useful option for definitive treatment of distal PCA aneurysms.


Subject(s)
Basilar Artery/surgery , Intracranial Aneurysm/surgery , Posterior Cerebral Artery/surgery , Aged , Cerebral Revascularization/methods , Female , Humans , Intracranial Aneurysm/diagnosis , Neurosurgical Procedures/methods , Vascular Surgical Procedures/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...